Novonesis A/s Class B · OMXCOP:NSIS_B
Novonesis A/s Class B — Novozymes — Q1 2017 Earnings Presentation
13 slides from Novonesis A/s Class B's earnings presentation, Apr 26, 2017
Slide 1: Novozymes Conference Call Q1 2017
Novozymes Conference Call Q1 2017 April 26, 2017
Slide 2: Good start to 2017 with solid progress on our strategic priorities
Good start to 2017 with solid progress on our strategic priorities • Resources deployed towards high-growth opportunities and growth markets, and we continue our investments in R&D to strengthen our technology leadership • Progress in our pipeline with two of our market-expanding opportunities advan
Slide 3: Sales and earnings on track in Q1 2017
Sales and earnings Organic sales growth for Q1 2017 at +3%. Q1 organic growth and DKKm on track in Q1 2017 Profitability in line with expectations +2% +4% -3% +6% +3% • Majority of our markets have developed well 3,714 3,740 3,609 since Q3 2016. Especially Bioenergy and 3,429 3,390 Food & Beverages
Slide 4: Household Care as expected in Q1
Household Care as expected in Q1 Q1 in line with expectations Quarterly organic growth and DKKm • Strong growth in automatic dish wash, driven by Europe +5% +4% -5% +5% +1% • Mixed developments within laundry: Good underlying 1,218 1,216 1,176 development in emerging markets, whereas accentuated 1,1
Slide 5: Good momentum in Bioenergy with 6% growth in Q1
Good momentum Positive start to 2017 as new innovation and higher ethanol production drive growth Quarterly organic growth and DKKm -6% -6% -8% +7% +6% in Bioenergy sales • Good development in US conventional biofuels 681 with 6% growth in supported by increased production and launch of our 663 626
Slide 6: Agriculture & Feed grew 2% in Q1, driven by strong feed sales
Agriculture & Feed Growth in animal health & nutrition offset by expected Quarterly organic growth and DKKm grew 2% in Q1, change in BioAg sales pattern -8% +13% -3% +22% +2% driven by strong • Sales of animal feed enzymes grew across markets and feed sales segments due to performance and favorable
Slide 7: Food & Beverages up 6% in Q1, driven by nutrition and starch
Food & Beverages Food & Beverages off to a good start in Q1 Quarterly organic growth and DKKm up 6% in Q1, • Starch in the emerging markets is contributing to growth +2% +4% -2% +4% +6% driven by nutrition due to a favorable development in corn pricing and recently launched innovation and starch 947
Slide 8: R&D update
R&D update Animal health & nutrition BioAg Conventional biofuels New strategic collaboration in probiotics Acceleron® B-200 SAT for soybeans in the US Spirizyme® T advanced suite of glucoamylases • Strategic collaboration with Boehringer • Enhanced isoflavonoid formulation that enables • Novozymes’
Slide 9: Progress in our pipeline
Progress in our pipeline During Q1 2017, our enhanced corn inoculant advanced to “Commercial” stage, while our grain-milling project progressed from “Discovery” to “Development” Total pipeline has: Area Innovation Feasibility Discovery Development Launch Commercial 8 programs with significant Househ
Slide 10: 2017 outlook maintained
2017 outlook maintained Q1 2017: High profitability in line with expectations Key financials Realized 2017 outlook (DKKm) Q1 2017 April 26 • Gross margin slightly up compared with Q1 last year. Productivity improvements increased the gross margin Sales growth +3% 2-5% Organic but were offset by nega
Slide 11: Good start to 2017 with solid progress on strategic agenda
• Good start to 2017 with solid progress on strategic agenda. Sales and earnings on track • Outlook maintained on all parameters • We continue to put resources behind our top innovation programs, deep partnerships and local market solutions • Our business is about turning amazing science into sustai
Slide 12: Forward-looking statements
Forward-looking statements This presentation and its related comments contain forward-looking statements, including statements about future events, future financial performance, plans, strategies and expectations. Forward-looking statements are associated with words such as, but not limited to, "bel
Slide 13: Q&A
Q&A • Good start to 2017 with solid progress on strategic agenda. Sales and earnings on track • Outlook maintained on all parameters • We continue to put resources behind our top innovation programs, deep partnerships and local market solutions • Our business is about turning amazing science into su